1-8 of 8
Keywords: acquired resistance
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles
Biochem Soc Trans (2014) 42 (4): 798–803.
Published: 11 August 2014
... factor that will undoubtedly influence therapeutic efficacy. 1 To whom correspondence should be addressed (email eric.oneill@oncology.ox.ac.uk ). 31 3 2014 © The Authors Journal compilation © 2014 Biochemical Society 2014 acquired resistance Akt alternative reading frame...
Articles
Biochem Soc Trans (2014) 42 (4): 822–830.
Published: 11 August 2014
... 2014 Biochemical Society 2014 acquired resistance breast cancer human epidermal growth factor receptor 2 (HER2) The HER (human epidermal growth factor receptor) family, comprising HER1 [more commonly referred to as EGFR (epidermal growth factor receptor)], HER2, HER3 and HER4...
Articles
Biochem Soc Trans (2014) 42 (4): 776–783.
Published: 11 August 2014
... of certain cancers. Despite these advances, however, only a subset of patients respond to these agents in the first instance, and, of those that do, acquired resistance invariably develops after several months. Studies in vitro have identified various mechanisms that can underpin intrinsic and acquired...
Articles
Biochem Soc Trans (2014) 42 (4): 791–797.
Published: 11 August 2014
... the role of signalling plasticity in the context of the mechanisms underlying both intrinsic and acquired resistance to targeted cancer therapies. We then examine the emerging analytical techniques and theoretical paradigms that are contributing to a greater understanding of signalling on a global...
Articles
Biochem Soc Trans (2014) 42 (4): 752–757.
Published: 11 August 2014
... by Astex Therapeutics Ltd and Cancer Research UK. 2 To whom correspondence should be addressed (email M.Michaelis@kent.ac.uk ). 5 2 2014 © The Authors Journal compilation © 2014 Biochemical Society 2014 acquired resistance murine double minute 2 inhibitor (MDM2 inhibitor...
Articles
Biochem Soc Trans (2014) 42 (4): 758–764.
Published: 11 August 2014
... acquired resistance mass spectrometry (MS) phosphoprotein signalling network therapeutic resistance Over the last two decades, monotherapies targeting aberrantly activated oncogenic kinases have emerged as frontline options for many human cancers. For these targeted therapeutics and for others...
Articles
Biochem Soc Trans (2013) 41 (4): 956–961.
Published: 18 July 2013
..., tumours are likely to adapt and acquire resistance to mTOR inhibitors. In the present article, we review studies that describe how tumour cells adapt to become resistant to mTOR inhibitors. mTOR is a central signalling hub which responds to an array of signalling inputs and activates a range of downstream...
Articles
Biochem Soc Trans (2012) 40 (1): 73–78.
Published: 19 January 2012
... and MEK1/2 inhibitors are currently undergoing clinical evaluation, but their ultimate success is likely to be limited by acquired drug resistance. We have used colorectal cancer cell lines harbouring mutations in B-Raf or K-Ras to model acquired resistance to the MEK1/2 inhibitor selumetinib (AZD6244...